Please use this identifier to cite or link to this item: http://hdl.handle.net/2440/112153
Citations
Scopus Web of Science® Altmetric
?
?
Type: Journal article
Title: A plasma biomarker panel of four MicroRNAs for the diagnosis of prostate cancer
Author: Matin, F.
Jeet, V.
Moya, L.
Selth, L.
Chambers, S.
Clements, J.
Batra, J.
Citation: Scientific Reports, 2018; 8(1):6653-1-6653-15
Publisher: Nature Publishing Group
Issue Date: 2018
ISSN: 2045-2322
2045-2322
Statement of
Responsibility: 
Farhana Matin, Varinder Jeet, Leire Moya, Luke A. Selth, Suzanne Chambers, Australian Prostate Cancer BioResource, Judith A. Clements and Jyotsna Batra
Abstract: Prostate cancer is diagnosed in over 1 million men every year globally, yet current diagnostic modalities are inadequate for identification of significant cancer and more reliable early diagnostic biomarkers are necessary for improved clinical management of prostate cancer patients. MicroRNAs (miRNAs) modulate important cellular processes/pathways contributing to cancer and are stably present in body fluids. In this study we profiled 372 cancer-associated miRNAs in plasma collected before (~60% patients) and after/during commencement of treatment (~40% patients), from age-matched prostate cancer patients and healthy controls, and observed elevated levels of 4 miRNAs - miR-4289, miR-326, miR-152-3p and miR-98-5p, which were validated in an independent cohort. The miRNA panel was able to differentiate between prostate cancer patients and controls (AUC = 0.88). Analysis of published miRNA transcriptomic data from clinical samples demonstrated low expression of miR-152-3p in tumour compared to adjacent non-malignant tissues. Overexpression of miR-152-3p increased proliferation and migration of prostate cancer cells, suggesting a role for this miRNA in prostate cancer pathogenesis, a concept that was supported by pathway analysis of predicted miR-152-3p target genes. In summary, a four miRNA panel, including miR-152-3p which likely targets genes with key roles in prostate cancer pathogenesis, has the potential to improve early prostate cancer diagnosis.
Keywords: Australian Prostate Cancer BioResource
Rights: © The Author(s) 2018. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
RMID: 0030086398
DOI: 10.1038/s41598-018-24424-w
Grant ID: http://purl.org/au-research/grants/nhmrc/614296
Appears in Collections:Medicine publications

Files in This Item:
File Description SizeFormat 
hdl_112153.pdfPublished version2.7 MBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.